You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
|
|---|---|
| Published in |
BMC Cancer, October 2011
|
| DOI | 10.1186/1471-2407-11-453 |
| Pubmed ID | |
| Authors |
Michael Eichbaum, Christine Mayer, Regina Eickhoff, Esther Bischofs, Gerhard Gebauer, Tanja Fehm, Florian Lenz, Hans-Christian Fricke, Erich Solomayer, Nikos Fersis, Marcus Schmidt, Markus Wallwiener, Andreas Schneeweiss, Christof Sohn |
| Abstract |
The prognosis of patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC) is poor. There is no standard treatment available. Emerging evidence suggests a major role for antiangiogenic treatment modalities in EOC, in particular in combination with the metronomic application of low dose chemotherapy. The novel, investigational oral antiangiogenic agent pazopanib targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit is currently being studied in different tumour types and is already used as first line therapy in recurrent renal cell carcinoma. A combined therapy consisting of pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, pretreated EOC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Netherlands | 1 | 1% |
| Unknown | 78 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 16% |
| Researcher | 11 | 14% |
| Student > Bachelor | 10 | 13% |
| Student > Master | 10 | 13% |
| Student > Doctoral Student | 7 | 9% |
| Other | 13 | 16% |
| Unknown | 16 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 45% |
| Nursing and Health Professions | 7 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Agricultural and Biological Sciences | 4 | 5% |
| Psychology | 3 | 4% |
| Other | 6 | 8% |
| Unknown | 20 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2011.
All research outputs
#15,237,301
of 22,655,397 outputs
Outputs from BMC Cancer
#4,098
of 8,237 outputs
Outputs of similar age
#95,396
of 139,451 outputs
Outputs of similar age from BMC Cancer
#49
of 93 outputs
Altmetric has tracked 22,655,397 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,237 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 139,451 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.